Literature DB >> 1894471

The significance of complement in proliferative vitreoretinopathy.

S Grisanti1, P Wiedemann, M Weller, K Heimann, K Zilles.   

Abstract

Complement is the principal effector arm of antibody-mediated allergic response and plays a central role in the pathogenesis of many immunologic disorders. The possible pathophysiologic importance of complement was examined in the development of proliferative vitreoretinopathy (PVR). Vitreous aspirates from patients with idiopathic PVR (n = 21) and traumatic PVR (n = 15) were examined for total vitreal protein (TVP) and complement components C3, C3d, C4, and C1q-fixed immunoglobulins using enzyme-linked immunosorbent assay (ELISA), sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and western blotting. The TVP, C3 components, and factor C4 were elevated significantly in diseased vitreous. The C3-TVP and C4-TVP ratios showed no difference between traumatic and idiopathic PVR. A C4 index to estimate the rate of intraocular C4 synthesis had a mean value of 3.2 (n = 15). The increased relative amount of C3d reflected complement activation in diseased vitreous. The negative values in normal human serum and plasma and in patient plasma samples (n = 15) indicated a local reaction in the eye. The authors found C1q-fixed immunoglobulin G; this may be the cause of complement activation by the classic pathway. These findings support the opinion that the cause of PVR may be based partly on an autoimmune reaction against ocular structures.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1894471

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  12 in total

1.  Enhanced expression of the complement factor H mRNA in proliferating human RPE cells.

Authors:  Norbert Kociok; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-08       Impact factor: 3.117

Review 2.  Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.

Authors:  D G Charteris
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

3.  HLA antigens and lymphocytes in proliferative vitreoretinopathy.

Authors:  R Proença; M Carvalho; D Proença; J Verissimo; I Regadas; A Travassos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-01       Impact factor: 3.117

4.  [Proteome analysis of undiluted vitreous humor in patients with branch retinal vein occlusion].

Authors:  I Dacheva; M Reich; M Nobl; K Ceglowska; J Wasiak; J Siwy; P Zürbig; H Mischak; F H J Koch; J Kopitz; F T A Kretz; T Tandogan; G U Auffarth; M J Koss
Journal:  Ophthalmologe       Date:  2018-03       Impact factor: 1.059

5.  Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy.

Authors:  M García-Ramírez; F Canals; C Hernández; N Colomé; C Ferrer; E Carrasco; J García-Arumí; R Simó
Journal:  Diabetologia       Date:  2007-03-23       Impact factor: 10.122

Review 6.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

Review 7.  [New developments in retinal detachment surgery].

Authors:  U Bartz-Schmidt; P Szurman; D Wong; B Kirchhof
Journal:  Ophthalmologe       Date:  2008-01       Impact factor: 1.059

8.  Immune response to specific molecules of the retina in proliferative vitreoretinal disorders.

Authors:  S Grisanti; K Heimann; P Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-05       Impact factor: 3.117

Review 9.  [Proliferative vitreoretinopathy process-To heal or not to heal].

Authors:  S Grisanti; S Priglinger; L Hattenbach
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

10.  Complement gene expression and regulation in mouse retina and retinal pigment epithelium/choroid.

Authors:  Chang Luo; Mei Chen; Heping Xu
Journal:  Mol Vis       Date:  2011-06-14       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.